BASI, a potent small molecular inhibitor, inhibits glioblastoma progression by targeting microrna-mediated β-catenin signaling

CNS Neuroscience and Therapeutics

Volumn 20, Issue 9, 2014, Pages 830-839

  Shi, Zhen Dong ^a   Qian, Xiao Min ^b   Zhang, Jun Xia ^c   Han, Lei ^a   Zhang, Kai Liang ^a   Chen, Lu Yue ^a   Zhou, Xuan ^a,d   Zhang, Jian Ning ^a   Kang, Chun Sheng ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

BASI; Glioblastoma; Inhibitor; MicroRNA; Catenin

Indexed keywords

ANTINEOPLASTIC AGENT; BASI; BETA CATENIN; MICRORNA; UNCLASSIFIED DRUG; BARLEY ALPHA-AMYLASE-SUBTILISIN INHIBITOR; CREBBP PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; MIRN181 MICRORNA, HUMAN; PROTEIN BINDING; SOYBEAN TRYPSIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR GROWTH; ANIMAL; BRAIN NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CFU COUNTING; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEUROBLASTOMA; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BETA CATENIN; BRAIN NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; CREB-BINDING PROTEIN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, NUDE; MICRORNAS; NEUROBLASTOMA; PROTEIN BINDING; SIGNAL TRANSDUCTION; TRYPSIN INHIBITOR, KUNITZ SOYBEAN;

EID: 84906074619     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12278     Document Type: Article

References (30)

1. Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology: The avenue to a cure for malignant glioma. CA Cancer J Clin 2010;60:166-193.
2. Tu Y, Gao X, Li G, et al. MicroRNA-218 inhibits glioma invasion, migration, proliferation, and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. Cancer Res 2013;73:6046-6055.
3. Shukla S, Pia Patric IR, Thinagararjan S, et al. A DNA methylation prognostic signature of glioblastoma: Identification of NPTX2-PTEN-NF-κB nexus. Cancer Res 2013;73:6563-6573.
4. Frattini V, Trifonov V, Chan JM, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 2013;45:1141-1149.
5. Pu P, Zhang Z, Kang C, et al. Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther 2009;16:351-361.
6. CarcinomaPolakis P. Drugging Wnt signalling in cancer. EMBO J 2012;31:2737-2746.
7. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012;149:1192-1205.
8. Shi Z, Qian X, Li L, et al. Nuclear translocation of beta-catenin is essential for glioma cell survival. J Neuroimmune Pharmacol 2012;7:892-903.
9. Shi ZD, Qian XM, Liu CY, et al. Aspirin-/TMZ-coloaded microspheres exert synergistic antiglioma efficacy via inhibition of beta-catenin transactivation. CNS Neurosci Ther 2013;19:98-108.
10. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-269.
11. Sun X, He Y, Huang C, Ma TT, Li J. Distinctive microRNA signature associated of neoplasms with the Wnt/beta-catenin signaling pathway. Cell Signal 2013;25:2805-2811.
12. Huang K, Zhang JX, Han L, et al. MicroRNA roles in beta-catenin pathway. Mol Cancer 2010;9:252.
13. Su J, Zhang A, Shi Z, et al. MicroRNA-200a suppresses the Wnt/beta-catenin signaling pathway by interacting with beta-catenin. Int J Oncol 2012;40:1162-1170.
14. Zhang KL, Han L, Chen LY, et al. Blockage of a miR-21/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas. Cancer Lett 2014;342:139-149.
15. Chen L, Han L, Zhang K, et al. VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1alpha/VEGF and beta-catenin/Tcf-4 signaling. Neuro Oncol 2012;14:1026-1036.
16. Shi Z, Zhang J, Qian X, et al. AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression. Cancer Res 2013;73:5519-5531.
17. Zhang J, Huang K, Shi Z, et al. High β-catenin/Tcf-4 activity confers glioma progression via direct regulation of AKT2 gene expression. Neuro Oncol 2011;13:600-609.
18. Obernosterer G, Martinez J, Alenius M. Locked nucleic acid-based in situ detection of microRNAs in mouse tissue sections. Nat Protoc 2007;2:1508-1514.
19. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013;13:11-26.
20. Wang XF, Shi ZM, Wang XR, et al. MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2. J Cancer Res Clin Oncol 2012;138:573-584.
21. Zhang W, Zhang J, Hoadley K, et al. miR-181d: A predictive glioblastoma biomarker that downregulates MGMT expression. Neuro Oncol 2012;14:712-719.
22. Yao H, Ashihara E, Maekawa T. Targeting the Wnt/beta-catenin signaling pathway in human cancers. Expert Opin Ther Targets 2011;15:873-887.
23. Watanabe K, Dai X. Winning WNT: Race to Wnt signaling inhibitors. Proc Natl Acad Sci USA 2011;108:5929-5930.
24. Takemaru KI, Moon RT. The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. J Cell Biol 2000;149:249-254.
25. Hao S, He W, Li Y, et al. Targeted inhibition of beta-catenin/CBP signaling ameliorates renal interstitial fibrosis. J Am Soc Nephrol 2011;22:1642-1653.
26. Henderson WR Jr, Chi EY, Ye X, et al. Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci USA 2010;107:14309-14314.
27. Gang EJ, Hsieh YT, Pham J, et al. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene 2013. doi: 10.1038/onc.2013.169. [Epub ahead of print].
28. He K, Xu T, Xu Y, et al. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/beta-catenin/CBP pathway. Int J Cancer 2014;134:43-54.
29. Yue X, Lan F, Yang W, et al. Interruption of beta-catenin suppresses the EGFR pathway by blocking multiple oncogenic targets in human glioma cells. Brain Res 2010;1366:27-37.
30. Mai BK, Viet MH, Li MS. Top leads for swine influenza A/H1N1 virus revealed by steered molecular dynamics approach. J Chem Inf Model 2010;50:2236-2247.